healthcare costs
Healthcare Procurement
Key Stakeholder Perceptions of Standard vs. Total Cost of Ownership: A Procurement Analysis for Orthopaedic-Powered Instruments
Aazad Abbas, Olumide Olotu, Sejla Abdic, Albert Yee, Jeremie Larouche, Cari Whyne, Dante Morra and J...
Editorial
Provinces and Territories Are Overdue for an Update in Healthcare Funding Policies
Jason M. Sutherland
Discussion and Debate
Multinational Pharmaceutical Companies Shortchange Canada in Research and Development Investments: Is It Time to Pursue Other Options?
Shoo K. Lee, Sukhy K. Mahl, Jessica J. Green and Joel Lexchin
Discussion and Debate
Commentary: Reconsidering Pharmaceutical Research and Development Investments
Marc-André Gagnon
Invited Paper
Expensive Drugs for Rare Diseases in Canada: What Value and At What Cost?
Sandra Sirrs, Helen Anderson, Bashir Jiwani, Larry D. Lynd, Eric Lun, Bob Nakagawa, Dean Regier, Shi...
Commentary
Specific, Fair and Transparent: A Canadian Process for Funding Drugs for Rare Diseases
Helen Stevenson
Commentary
What Procedural Ethics Can Learn from the Quest for Moral Justification for the “Rule of Rescue”
Bernard Keating
Commentary
Expensive Drug Prices for Rare Cancers: Are Patients Truly Benefitting?
Kristina Jenei and Bishal Gyawali